Pfizer sells off BMS rival drugs to startup
To view this email as a web page, click here

Today's Rundown

 

Featured Story

Moderna finally cracks into gene editing with Metagenomi pact thanks to 'irresistible' data

We finally know who Moderna has been courting behind the scenes to make the big jump into gene editing. The famed biotech has signed a research partnership with CRISPR gene editing company Metagenomi.

read more

Top Stories

Legend's status put on hold as FDA delays Janssen-partnered CAR-T decision

Legend Biotech and Johnson & Johnson have been hit by an FDA delay for their cell therapy blood cancer hopeful ciltacabtagene autoleucel.

read more

Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers

Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of inflammatory diseases, the Big Pharma is offloading the portfolio to a new company in return for a 25% stake in the startup.

read more

Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success

Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention.

read more

6 weeks in, Mirati CEO shows CMO, COO the door ahead of key FDA filing for KRAS drug

In the lead up to asking the FDA for its first drug approval, Mirati Therapeutics is making another leadership shuffle, parting ways with its chief medical officer and chief operating officer six weeks into the new CEO's tenure.

read more

Sponsored: Intranasals in Clinic Now Positioned for $71 Billion Nasal Delivery Market

Australia’s Avance Clinical: how intranasal biotechs can expedite trials with rapid approval processes - including no IND and a 43.5% incentive rebate - to tap $71 billion market

read more

Pfizer, GSK present dueling maternal vaccine data in RSV, as an analyst predicts 'the year of RSV' is ahead

The head-to-head Big Pharma battle for a respiratory syncytial virus vaccine is heating up, with Pfizer reporting 85% efficacy in protecting babies born to vaccinated mothers from infection or hospitalization.

read more

Aldeyra’s dry eye drug helps with redness but misses other important phase 2 goals

Aldeyra Therapeutics’ dry eye drug helped relieve ocular redness in a phase 2 trial but merely “approached statistical significance” on a secondary endpoint of wetness in the eye.  We know you’re here for the unspun version of this story, and this is it: the secondary goal was not met.

read more

Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech

The search for an edge in the hot protein degrader space has led Novartis to Dunad Therapeutics. By putting up $24 million and committing to $1.3 billion in biobucks, Novartis has secured the chance to option candidates against up to four targets worked on by its new partner.

read more

AbbVie-backed Nitrome adds BMS as investor in $45M series A, snags Nurix CBO as CEO and rebrands to Nitrase

Nitrome Biosciences rebranded to Nitrase Therapeutics to represent the new class of enzymes it discovered and added Bristol Myers Squibb as an investor. The biotech's refresh was completed by poaching former Nurix Therapeutics Chief Business Officer Pierre Beaurang as CEO.

read more

The top 10 highest-paid medtech CEOs

The COVID-19 pandemic presented a once-in-a-generation challenge for the medtech industry, and many of the CEOs on this list met it head-on.

read more

Federal judge rules HHS' efforts to punish pharma over 340B restrictions 'arbitrary and capricious'

Although the court turned aside HHS efforts to penalize drugmakers restricting discounted 340B products from contract pharmacies, the judge took a shot at the the restrictions themselves and opened the door for legislators to settle the issue.

read more

Resources

Whitepaper: Create a seamless experience across eConsent, eCOA & more

Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper.

2021 Report: Clinical Trial Management in a Post-Pandemic World

New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic.

Whitepaper: A Checklist for eCOA Solution Deployment

Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

Paid Marketplace: Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events